HUTCHMED (China) Limited (Nasdaq/AIM: HCM; SEHK:13) will release its 2024 financial results on Wednesday, March 19, 2025. The announcement is scheduled for 7:00 am EDT / 11:00 am GMT / 7:00 pm HKT.

A conference call and webcast, including a Q&A session with HUTCHMED’s leadership, is planned for analysts and investors.

This English-language call and webcast will begin at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on March 19, 2025. A Mandarin Chinese webcast will also be available at 12:30 am GMT / 8:30 am HKT on March 20, 2025 (8:30 pm EDT on March 19, 2025). Both webcasts will stream live on the company website. The presentation slides will be accessible for download prior to the call. Dial-in details will be included in the results announcement and on the company website. A recording will be posted online soon after the event concludes.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is a commercial-stage biopharmaceutical company focused on innovative targeted and immunotherapies for cancer and immunological diseases. HUTCHMED has a history of advancing in-house discoveries to patients globally, with three medicines currently marketed in China; one of these is also approved in the US, Europe, and Japan. For more information, please visit: or follow us on .

CONTACTS

Investor Enquiries +852 2121 8200 /
   
Media Enquiries  
FTI Consulting – +44 20 3727 1030 /
     Ben Atwell / Alex Shaw      +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) /
   
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500
   
HSBC Joint Broker
Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888
   
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500

“`